Summary
Aging is often accompanied by a dramatic increase in cancer susceptibility. To gain insights into how aging affects tumor susceptibility, we generated a conditional mouse model in which oncogenic Kras G12D was activated specifically in lungs of young (3–5 months) and old (19–24 months) mice. Activation of Kras G12D in old mice resulted in shorter survival and development of higher‐grade lung tumors. Six weeks after Kras G12D activation, old lung tissues contained higher numbers of adenomas than their young tissue counterparts. Lung tumors in old mice displayed higher proliferation rates, as well as attenuated DNA damage and p53 tumor suppressor responses. Gene expression comparison of lung tumors from young and old mice revealed upregulation of extracellular matrix‐related genes in young tumors, indicative of a robust cancer‐associated fibroblast response. In old tumors, numerous inflammation‐related genes such as Ccl7,IL‐1β, Cxcr6, and IL‐15ra were consistently upregulated. Increased numbers of immune cells were localized around the periphery of lung adenomas from old mice. Our experiments indicate that more aggressive lung tumor formation in older Kras G12D mice may be in part the result of subdued tumor suppressor and DNA damage responses, an enhanced inflammatory milieu, and a more accommodating tissue microenvironment.
Keywords: aging, cancer, inflammation, Kras, p53, tumor microenvironment
Introduction
Cancer is an age‐associated disease. While cancer occurs at all ages, overall cancer risk rises exponentially with age. Humans exhibit rapidly increasing cancer rates starting in the sixth decade of life (DePinho, 2000; Campisi, 2003). In the laboratory, most inbred mouse strains with a maximum lifespan of 24–36 months begin to show exponential increases in cancer risk after 18 months. While many mouse cancer models and a modest number of mouse aging models have been developed and characterized, the direct relationship between cancer and aging has rarely been explored in either cancer or aging models. Given the complexities of both processes in mammalian organisms, devising definitive experiments to understand specific causal mechanisms in the aging–cancer relationship has been a major challenge.
Multiple theories have been proposed to explain the age dependence of somatically arising cancers. As early as the 1950s, it was hypothesized that cancers were a product of a multistep genetic lesions arising somatically in specific cells (Nordling, 1953; Armitage & Doll, 1954). Cancer genome sequencing has confirmed that the vast majority of individual cancers display mutations in multiple genes known functionally to be cancer driver genes (Lawrence et al., 2013). Thus, the age dependence of cancer is likely driven in large measure by the statistical likelihood over time that a given set of complementary driver mutations occurs within a single normal cell that transforms it into a malignant cancer cell. Recently, the multistage carcinogenesis model has been further refined by Tomasetti & Vogelstein (2015) to show that lifetime risk of a cancer type correlates with total number of normal stem/progenitor cell divisions that maintain homeostasis within the tissue of origin. Two‐thirds of cancers were estimated to be caused by stochastic replication errors in self‐renewing cells within a tissue.
Despite the elegance of the above model, it may be incomplete because of its focus on cell autonomous genetic events in the evolving cancer cell. Different cancer types arise at similar rates even though their stem cell pools may have very different sizes, division rates, and mutational spectra. As proposed by Rozhok & DeGregori (2015), noncell autonomous processes such as age‐dependent tissue microenvironmental changes may play an important role in accelerating cancer development. The aged tissue microenvironment may provide a selective advantage in enhancing the oncogenic effects of mutated cancer driver genes compared to the youthful tissue microenvironment. Campisi and collaborators have demonstrated that senescent fibroblasts were more effective than young fibroblasts in stimulating premalignant and malignant epithelial cells to proliferate in vitro and to form tumors in mice (Krtolica et al., 2001). This senescence‐dependent tumorigenic effect was driven in part by secretion of an array of growth stimulatory inflammatory cytokines (Coppe et al., 2010). Indeed, chronic low‐grade inflammation, also known as ‘inflammaging’, is frequently seen in old age and is strongly correlated with mortality (Lopez‐Otin et al., 2013; Morrisette‐Thomas et al., 2014). Many genes associated with inflammation and immune responses are shown to be increased in aged tissues from humans and rodents (de Magalhaes et al., 2009). Thus, as more stromal cells undergo senescence in the aging tumor microenvironment, the activation of the senescence‐associated secretory phenotype (SASP) may stimulate progression of oncogenically activated premalignant cells in the vicinity.
To examine potential mechanisms of age‐associated tumorigenesis in an intact animal, we used a genetically engineered conditional mouse model of lung cancer. A Cre recombinase‐inducible mutant Kras G12D allele was specifically activated in lungs by inhalation of Cre adenovirus (DuPage et al., 2009) to study age‐associated differences in lung tumor formation. KRAS mutations represent potent oncogenic driver events that occur in 35% of lung cancers and 30% of all human cancers (Wilson & Tolias, 2016). We compared the tumorigenic effects of Kras G12D activation in young (3–5 months) and old mice (19–24 months). We hypothesized that if tumors showed more rapid development and progression in the old Kras‐induced mice, this would be more supportive of models emphasizing cell‐nonautonomous mechanisms rather than strict cell autonomous mutational mechanisms. Genomic mutation loads in mice increase less than twofold between 4 and 20 months of age (Vijg et al., 2005), so a strict mutational model would not be expected to produce dramatic differences in tumorigenesis between young and old mice. In fact, we did observe significantly accelerated tumorigenesis and the appearance of higher‐grade lung tumors in old mice. Further analyses to identify molecular mechanisms showed attenuated tumor suppressor pathway responses and DNA damage responses in lung tumors from old mice relative to their young counterparts. Evidence of differential noncell autonomous effects included likely enhanced activation of fibroblast‐secreted extracellular matrix (ECM) components in young tumors and immune cell secretion of inflammatory cytokines in older tumors. We propose that the combination of cell intrinsic attenuated tumor suppressor/DNA damage responses and cell extrinsic tumor microenvironment fibroblast functions and immune cell inflammatory cytokine effects play significant roles in the enhanced tumorigenesis observed in the older Kras G12D mice.
Results
Establishing the inducible bi‐allelic Kras G12D ; LacZ model and confirmation of comparable Kras G12D activation in young and old mice
To achieve expression of oncogenic KrasG12D along with a reporter gene, we generated bi‐allelic Kras G12D; LacZ mice by crossing Lox‐Stop‐Lox‐Kras G12D (LSL‐Kras G12D) mice with Rosa26‐LSL LacZ mice (Fig. 1A). In the resulting bi‐allelic mice, both the Kras G12D and Rosa26‐LacZ alleles are preceded by a LoxP‐flanked stop cassette that prevents transcription of the downstream gene. When Cre recombinase is delivered via adenovirus expressing Cre, it binds to the LoxP recombination sites and deletes the LSL cassette, activating transcription of Kras G12D and LacZ. Intranasal administration of Cre adenovirus in young (3–5 months) and old (19–24 months) mice would result in deletion of the LSL cassettes and expression of LacZ and Kras G12D in lungs of bi‐allelic Kras G12D; LacZ mice (Fig. 1A). For simplicity, the bi‐allelic Kras G12D; LacZ mice will henceforth be referred to as Kras G12D mice. LacZ reporter gene expression was used to address variation in rates of activation by Cre adenovirus, as the nature of intranasal instillation entails some variability in the delivery of Cre adenovirus to individual lungs. Immunofluorescence analysis for β‐galactosidase (β‐gal) in lung sections from young (4 months) and old (24 months) LacZ control mice averaged roughly similar levels of staining at 6 weeks postinstillation (Fig. 1B and Fig. S1A). Western blot analysis showed increased pErk1/2 expression indicating activated KRasG12D signaling in lungs harvested 6 weeks postinstillation from Kras G12D mice (young and old) (Fig. S1B). Despite some mouse to mouse variability, there were no remarkable differences in LacZ expression between young and old mice at 6 weeks post‐Cre adenovirus. Also, increased detection of β‐gal in bi‐allelic mice relative to LacZ controls indicates preferential proliferation of adenovirus‐transduced KrasG12D and β‐gal expressing cells (Fig. S1B). LSL recombination was compared using genomic DNA and primers for the recombined LacZ gene in control lungs harvested 6 weeks post‐Cre adenovirus (Fig. S1C). Despite some variability, no significant age‐related differences were found in the LSL recombination for LacZ. Thus, LSL recombination (Fig. S1) and β‐gal expression (Fig. 1B and Fig. S1A,B) did not display significant differences between young and old Kras G12D mice, indicating similar fractions of lung cells with activated Kras G12D at 6 weeks post‐Cre. Lungs harvested 2 weeks post‐Cre were also subjected to Western blot analyses for β‐gal. Lungs from Kras G12D mice expressed more β‐gal than matched LacZ control lungs (Fig. S2A). Further, β‐gal expression in lungs was assessed by X‐gal staining. In agreement with immunoblot data, Kras G12D mice showed enhanced X‐gal staining relative to control LacZ mice due to hyperproliferation induced by activated Kras G12D (Fig. S2B). Similar to our previous Western blot data, β‐gal expression in old mice is equivalent or slightly lower than young mice at 2 weeks post‐Cre adenovirus.
Lungs from Cre adenovirus‐instilled Kras G12D mice showed hyperproliferation leading to different grades of lung lesions previously reported in mouse lung tumor models (Jackson et al., 2001; DuPage et al., 2009) such as bronchioloalveolar hyperplasia, adenoma, and adenocarcinoma (Fig. 1C, Methods S1). In this study, lung adenoma with atypia is a subclassification of lung adenoma that consisted of adenoma with additional presence of clusters of 10 or more atypical cells that had enlarged and pleomorphic nuclei, but no other features of malignancy. Unless explicitly mentioned, adenoma in the text refers to all adenomas (including adenoma with atypia).
Old Kras G12D mice show shorter survival and more advanced end‐stage lung tumors
To compare the long‐term effect of age on tumor formation and progression, young (3–5 months) and old (19–20 months) Kras G12D mice were subjected to Cre adenovirus instillation and tumor latency analysis. Comparative analysis of tumor latency showed old activated Kras G12D mice with significantly reduced survival as compared to young activated Kras G12D mice (P = 0.0004) (Fig. 2A, Data S1). Both young and old age‐matched control LacZ mice showed no mortality for the duration of the study (200 days). Lung tumors harvested terminally in the latency study were assessed histopathologically and classified as adenoma or adenocarcinoma on hematoxylin and eosin (H&E)‐stained lung sections. These lungs also displayed areas of severe hyperplasia but only clearly defined lesions of adenoma and adenocarcinoma were included for this detailed analysis. Histopathological analysis of lung tumors from young Kras G12D mice revealed that ~ 80% of lung tumors were adenoma lesions and 20% of tumors were adenocarcinoma lesions. In contrast, a significantly higher proportion of old Kras G12D mice lung tumors were adenocarcinoma (~ 50%) and a lower proportion of tumors were adenoma (~ 50%) (Fig. 2B). In addition, tumor area evaluation indicated that old Kras G12D mice displayed significantly larger adenoma lesions than adenomas from young Kras G12D mice (Fig. 2C,D). There were no significant differences observed in total lung tumor area (Fig. 2E) and number of lung tumors (adenoma plus adenocarcinoma) between young and old Kras G12D mice (not shown) indicating comparable tumor burden at the moribund stage. Collectively, these data indicate slower growing and lower grade tumors arising in young mice associated with longer survival post‐Cre induction. No distant metastases were observed in the Kras G12D mice.
Short‐term studies reveal old Kras G12D mice with more aggressive tumors
To test whether the more aggressive lung tumor phenotype in old Kras G12D mice appears at earlier time points after Kras activation, lungs of young (3–5 months) and old (22–24 months) activated Kras G12D mice were examined histopathologically 6 weeks after intranasal instillation with Cre adenovirus. The average number of tumors (adenoma plus adenocarcinoma) observed in H&E‐stained sections in old Kras G12D mice significantly exceeded the number of tumors observed in lung sections from young Kras G12D mice (Fig. 3A). Further analysis of lung lesions revealed much higher number of adenomas in old Kras G12D mice as compared to young Kras G12D mice (Fig. 3B). Subclassification of adenomas into adenoma with no atypia and adenoma with atypia revealed significantly higher number of adenoma with atypia in old Kras G12D mice (>Fig. S3). Similarly, adenocarcinoma was observed in 3/19 old Kras G12D mice but not in young Kras G12D mice (Fig. 3B). Comparative analysis of areas of all adenoma lesions revealed significantly larger adenoma lesions in old Kras G12D mice than in young Kras G12D mice (Fig. 3C). Hyperplasia was also compared in lungs from young and old mice. The hyperplastic epithelial cells were enlarged and stained intensely with antibody for keratin 8 (Fig. 3D). Closer examination of H&E‐stained sections of lungs showed that these mildly hyperplastic areas of lung have enlarged/hypertrophic alveolar epithelial cells with increased cytoplasm and larger nuclei than normal (Fig. 3E,F). The morphometric quantification of hyperplastic areas distinguished by intense keratin 8 and H&E staining revealed a higher percentage of the total area of bronchioloalveolar hyperplastic regions in young Kras G12D mice than in old Kras G12D mice (Fig. 3G), in contrast with observations of more advanced tumor types.
Higher proliferative index observed in old Kras G12D tumors
The incidence of more aggressive lung tumors in old Kras G12D mice led us to explore the molecular mechanisms responsible for phenotype differences. For all subsequent analyses, lungs from young (3–5 months) and old (22–24 months) Kras G12D mice were harvested 6 weeks post‐Kras G12D activation. Proliferation marker Ki67 staining of lung tumors showed increased numbers of positively stained cells in adenomas from old Kras G12D mice. Quantitative analysis of Ki67‐stained nuclei showed higher proliferative indexes in lung adenoma lesions from old Kras G12D mice as compared to young Kras G12D mice (Fig. 4A,B). However, we did not observe significant differences in Ki67 staining in hyperplastic tissues from young and old Kras G12D mice (Fig. S4A).
The DNA damage response is attenuated in old Kras G12D mice
The DNA damage response in premalignant tumors acts as a barrier to cancer progression following oncogene‐induced replication stress and DNA double‐strand breaks associated with cell proliferation (Halazonetis et al., 2008). We investigated whether the DNA damage response differs in young and old mice with activated KRasG12D signaling. γH2AX is a critical DNA damage repair protein activated in premalignant lesions that localizes to DNA strand breaks resulting from replication stress (Kinner et al., 2008). In the six‐week study, all of the 16 adenoma lesions analyzed from young Kras G12D mice (n = 8) were positive for γH2AX staining, whereas 64% (16/25) of the adenoma lesions from old Kras G12D mice (n = 9) were positive for γH2AX staining (Fig. 4C,D). The γH2AX‐positive tumors had 80–90% cells with γH2AX foci irrespective of age (Fig. S4B), and γH2AX‐negative tumors had at least 90% of cells with no γH2AX foci (not shown). Transcript levels of DNA damage‐induced tumor suppressor Gadd45a were significantly downregulated in healthy lungs and tumors from old mice as compared to young counterparts (Fig. 4E) indicating a blunted DNA damage response with increased age.
Tumor suppressor responses are less robust in premalignant lesions from old Kras G12D mice
Oncogene‐induced cell proliferation activates tumor suppressor responses that deter further tumor progression. Hence, we sought to examine the effects of age on tumor suppressor responses by p53, p19Arf, p16Ink4a, p27Kip1, and p21Cip1. Lungs from old and young Kras G12D mice harvested 6 weeks after Cre adenovirus instillation were stained for tumor suppressor p53 protein (green). Keratin 8 (red) was used to mark hyperplastic epithelial lesions in lungs. Hyperplastic areas from young Kras G12D mice showed more intense and widespread p53 induction (Fig. 4F, first panel) relative to hyperplastic lung areas from old Kras G12D mice (Fig. 4F, second panel). Nuclear p53 intensity was quantified for multiple hyperplastic lung areas, and old Kras G12D mice showed significantly reduced p53 staining in hyperplasias compared to their young mouse counterparts (Fig. 4G). Similarly, adenomas from young and old Kras G12D mice were assessed for p53 upregulation. Overall, there was less nuclear p53 expression in adenomas from old Kras G12D mice (Fig. 4H,I). Lung adenocarcinomas from old Kras G12D mice showed minimal p53 staining consistent with the advanced nature of those tumors (Fig. 4J). These data indicate that aging inhibits timely and efficient onset of the p53 tumor suppressor response in a premalignant context.
We also assessed the mRNA levels of p19Arf and p16Ink4a in lung lesions from young and old Kras G12D mice (Fig. S4C,D). As previously reported for these tumor suppressors (Krishnamurthy et al., 2004), normal lung tissues of old mice showed significantly higher levels of p19Arf and p16Ink4a RNA compared to young mice. p19Arf and p16Ink4a RNA were significantly upregulated in lung lesions from young mice, indicating an intact p16/p19 tumor suppressor response. However, further increases in p19Arf and p16Ink4a RNA were not observed in old lung lesions relative to already elevated levels of these RNAs observed in age‐matched normal lung tissue, suggesting the absence of an induction of significant tumor suppressor response to oncogenic stimulus in older mice. Similarly, p21Cip1 mRNA levels were induced in lung tumors of young Kras G12D mice but not in lung tumors of old Kras G12D mice when compared to age‐matched controls (Fig. S4E). Finally, no significant differences were found between young and old Kras G12D mice lung adenomas for p27Kip1 protein staining (Fig. S4F,G).
DNA methylation analyses reveal hypermethylation of the Cadherin 13 promoter in lungs of old mice
Aberrant DNA methylation is common in cancer and aging (Sandoval & Esteller, 2012; Jung & Pfeifer, 2015). We examined global and site‐specific changes in DNA methylation in our lung cancer model. Global methylation levels assessed by quantitative bisulfite pyrosequencing of retrotransposons IAP and line‐1 showed no methylation changes in healthy lung tissue and lung tumors as a function of age (Fig. S5A,B). One tumor suppressor that is shown to be downregulated and hypermethylated in many cancers (including lung cancer) is cadherin 13 (CDH13). (Andreeva & Kutuzov, 2010; Xue et al., 2014). Based on microarray data from Kras G12D mice derived lung lesions, validation by qRT–PCR showed twofold downregulation of Cdh13 in healthy lung and lung lesions from old mice (Fig. S5C). Next, we examined epigenetic changes in the Cdh13 promoter region in lungs from young and old mice. The Cdh13 promoter was found to be significantly hypermethylated in old normal lungs relative to young normal lungs (Fig. S5D) and in lung premalignant lesions from old mice relative to their young lung lesion counterparts (Fig. S5E). Examination of the aging‐relevant Cdkn2a (encoding p16Ink4a) gene showed that its promoter was moderately more hypermethylated in normal lungs of old mice relative to young mice, but no significant differences in Cdkn2a promoter methylation were found in lung tumors from young and old Kras G12D mice (Fig. S5F).
RNA expression analyses reveal changes in the tumor microenvironment of young and old Kras G12D mice
Microarray expression analysis was performed on four young and four old Kras G12D adenomas 6 weeks after KrasG12D activation. Statistical comparison of the young and old lesions revealed 359 genes significantly increased in RNA expression in young tumors relative to old tumors (Table S1, Fig. 5A). Gene Set Enrichment Analysis (GSEA) of the 359 genes showed a highly significant enrichment in canonical pathways related to the ECM and genes specific to cancer‐associated fibroblasts (CAFs) (Table S2, Fig. 5B). Numerous collagens and other ECM structural molecules such as Sparc, Lama2, and Fbn1 were significantly upregulated in the young tumors. Standard CAF marker genes such as alpha smooth muscle actin (Acta2), Pdgfb, Pdgfrb, and Mmp2 exhibited increased expression in the young lesions. Since gene expression patterns are derived from tumor lesions with mixed populations of cells, key CAF marker gene Acta2 expression was further examined using immunostaining. Antibody staining of young and old Kras G12D tumor sections for smooth muscle actin protein expression showed overall enhanced staining in young tumors relative to old tumors, although differences did not reach significance (Fig. S6). Given that most of these differentially regulated genes are primarily expressed in fibroblasts, these results suggest that the expression differences in the young and old lesions arise from the tumor‐associated stroma rather than the epithelial lesions themselves.
Statistical analysis of RNA expression also revealed that 176 genes were significantly upregulated in the old adenomas (Table S3, Fig. 6A). GSEA on this gene set showed a dramatic enrichment of immune cell markers and cytokines and chemokines associated with inflammatory pathway gene expression, including IL‐1β, IL‐7, Ccl3, Ccl7, Ccl9, and Osm (Table S4, Fig. 6B). Other immune‐related genes were intracellular immune signaling genes, suggesting that increased numbers of immune cells were contributing to the old lesion expression signature. Some ECM genes were also upregulated in the old tumors, indicating that both CAFs and immune cells were present, and inflammatory gene products known to be secreted by senescent fibroblasts (SASP markers) were noted (IL‐1β, IL‐7, Ccl3) (Fig. 6B).
Increased inflammatory pathway activation in old mouse normal tissues and tumors
Validation of the microarray results by qPCR showed many inflammation‐associated genes (Ccl7, IL‐15ra, IL‐1β, and Cxcr6) as significantly upregulated in lung lesions from old Kras G12D mice (Fig. 6C–F). Of these, interleukin‐1β (IL‐1β) showed age‐dependent upregulation in control lungs and tumors from old mice, whereas tumor‐specific upregulation was observed for Ccl7, IL‐15ra, and Cxcr6 cytokines in old mice. In conjunction with increased cytokine levels detected in lung tumors from old mice, immunofluorescence analysis using αCD45 and αF4/80 showed increased accumulation of leukocytes and macrophages in close proximity to tumors from old mice (Fig. 6G,H, Fig. S7). Irrespective of age, most of the immune cells were present at the tumor periphery and not within the core of the tumors (Fig. S7).
The cytokine milieu plays a significant role in tumor promotion and progression. To further explore the age‐related inflammatory responses on associated lung tumors, broncho‐alveolar lung lavage fluid (BALF) from young and old Kras G12D mice 6 weeks after Cre adenovirus instillation was subjected to cytokine analysis. Luminex analysis showed that monocyte chemotactic protein, MCP‐1 (CCL2), was significantly elevated in BALF from old Kras G12D mice (Fig. S8A). Another key cytokine, IL‐6, that plays an important role in tumor progression, was higher in 5/12 old Kras G12D mice when compared to average levels of IL‐6 in young Kras G12D mice (n = 14). However, IL‐6 levels in BALF showed large variations and did not satisfy the test of significance (P = 0.1) when compared to BALF levels from young Kras G12D mice (Fig. S8B). The number of macrophages (P = 0.1), lymphocytes (P = 0.2), polymorphonuclear cells (P = 0.08), and total number of leukocytes (P = 0.08) in BALF from old Kras G12D mice tended to be elevated as compared to young Kras G12D mice (Fig. S8). Immune cell numbers in BALF from young and old controls were equivalent. The IL‐1β cytokine primarily secreted by activated macrophages is involved in inflammatory and immune response by inducing pro‐inflammatory genes such as IL‐6 and IL‐8. The serum level of IL‐1β was significantly higher in old Kras G12D mice than in young Kras G12D mice (Fig. S8D). The p38 MAPK signaling plays a key role in the production of several inflammatory regulators. Thus, lung sections from young and old Kras G12D mice were subjected to phospho‐p38 MAPK staining and lung tumors from old Kras G12D mice showed increased staining (Fig. S8E).
The activated inflammatory milieu as a function of age was further corroborated by experiments where differences were observed between young and old LacZ mice. Thus, serum levels for many cytokines such as IL‐6, IP‐10 (interferon‐induced protein‐10 also known as Cxcl10), MCP‐1 (monocyte chemoattractant protein‐1, also known as Ccl2), MIP‐2 (macrophage inflammatory protein‐2, also known as Cxcl2), and RANTES/Ccl5 were significantly elevated in old LacZ mice as compared to young LacZ mice (Fig. S9A). Similarly, lungs from old LacZ control mice showed higher levels of cytokines such as Cxcl2 and Cxcr2 by real‐time PCR analyses indicating elevated IL‐8 signaling (Fig. S9B‐C).
Discussion
We sought to investigate the mechanisms by which aging tissues might influence cancer initiation and progression. Using a genetically engineered mouse model of inducible lung cancer, we examined the effects of activating the potent oncogene Kras G12D in young (3–5 months of age) and old mice (19–24 months of age). Lung‐specific activation of KrasG12D resulted in hyperproliferation of the lung epithelial cells leading to hyperplasia, adenoma, and adenocarcinoma development in the lungs. Both long‐term survival and short‐term 6‐week studies showed accelerated rates of tumorigenesis with more aggressive tumors in 19‐ to 24‐month Kras G12D mice compared to their 3‐ to 5‐month counterparts. Significantly larger adenoma lesions were seen in old Kras G12D mice and in the timed 6‐week studies, only the old Kras G12D mice developed malignant adenocarcinomas (Figs 2A–D and 3A–C). In contrast to old Kras G12D mice, the young mice displayed larger numbers of lower grade broncho‐alveolar hyperplasias in the 6‐week study (Fig. 3G). One interpretation for this result is that preneoplastic lesions such as hyperplasias may arise at roughly similar rates in young and old mice in response to Kras G12D activation, but intrinsic and extrinsic processes in the young lung tissues are more effective in preventing progression of hyperplastic lesions to adenomas and adenocarcinomas.
Hyperproliferation induced by oncogene activation has been shown to be associated with replication stress and aberrant DNA strand breaks that activate the DNA damage response, forming a barrier to malignant progression (Halazonetis et al., 2008). With age, there is also accumulation of DNA lesions with unrepairable double‐strand breaks marked with γH2AX foci (Sedelnikova et al., 2004; Halazonetis et al., 2008; Schurman et al., 2012). Our data revealed reduced γH2AX staining in adenomas of old Kras G12D mice compared to adenomas in the young Kras G12D mice (Fig. 4C,D). Many of these lung adenomas in older mice had foci of neoplastic cells with cellular atypia as assessed by histopathological evaluation. In addition, DNA damage‐induced tumor suppressor Gadd45a transcripts were lower in healthy lungs and tumors from old mice (Fig. 4E). These data support the idea that premalignant cells in older tissues have a less robust DNA damage response than their younger counterparts.
The DNA damage response and the p53 tumor suppressor response are intertwined as damage response kinases activate p53 as well as DNA repair pathways (Sperka et al., 2012). The p53 damage response has been shown to decline with age in response to DNA damage in spleen and thymus of mice (Feng et al., 2007). In other studies, p53 activity was found to be upregulated in noncancerous tissues of aged mice (Edwards et al., 2007; Ugalde et al., 2011). We found a less efficient p53 tumor suppressor response, as measured by protein expression, in lung adenomas and hyperplasias from old Kras G12D mice. Analysis of other tumor suppressors shows that p19Arf and p16Ink4a are increased in expression in older normal mouse lung tissues, consistent with earlier findings that increased expression of these two genes is a general biomarker of normal tissue aging (Krishnamurthy et al., 2004). However, with induction of Kras G12D, only young mouse adenomas show significant increases in p16Ink4a and 19Arf mRNA. Similarly, p21Cip1 mRNA levels are significantly upregulated in response to Kras G12D only in lung tumors from young Kras G12D mice but not in lung tumors from old Kras G12D mice relative to normal lung tissue (Fig. S4E). Such robust tumor suppressor upregulation in response to oncogenic stimulus specifically in young mice could represent an additional cancer progression barrier not available to older cells that already have high levels of expressed p16Ink4A, p19Arf, and p21Cip1 prior to oncogene activation.
In the discussion above, we focused on intrinsic factors specific to the developing lung cancer cell. However, extrinsic factors, particularly the tumor microenvironment, have been shown to play a major role in influencing the progression of a cancer lesion. A key component of the tumor microenvironment is the CAF that can become activated and reprogrammed by cancer cells to enhance synthesis of ECM structures and to secrete factors that attract immune cells of various types (Kalluri, 2016). Comparison of the global gene expression signatures of the young and old Kras G12D lung tumors shows that the young tumors preferentially express genes characteristic of activated CAFs and actively produce ECM components relative to their older counterparts. In contrast, the old tumors show preferential chemokine and cytokine expression as well as immune cell markers indicating a higher density of immune cells within the tumor microenvironment. Consistent with this, immunofluorescence analyses revealed elevated levels of immune cells in close proximity to the lung adenomas from old mice. While the increased cytokine expression in older tumors observed in Fig. 6A could be in part a result of larger tumor size (and thus more immune cells) in the older animals, our immunofluorescence scoring of immune cells in tumors was based on immune cell density (Fig. S7) and this density was significantly higher in older tumors independent of tumor size (Fig. 6G,H). Tumor‐derived chemotactic factors such as Ccl2, Ccl3, Ccl5, and Ccl7 are known to recruit macrophages to the growing tumor (Pollard, 2004; Sica et al., 2008). Additionally, enhanced inflammatory chemokine/cytokine expression has been shown to be a prominent phenotype in senescent fibroblasts that serve to directly and indirectly (in part through recruitment of tumor promoting immune cells) promote cancer cell growth and survival (Coppe et al., 2010; Lopez‐Otin et al., 2013). Other recent studies have emphasized the influence of contexts such as altered tissue microenvironment on age‐dependent incidence of cancers (Lasry & Ben‐Neriah, 2015; Rozhok & DeGregori, 2015).
Both aging and cancer being multifactorial pathophysiological states, it is not surprising that numerous factors work together and play an important role in the progression of cancer as a function of age. As illustrated in Fig. S10 (Supporting Information), our data point to an age‐dependent interplay between the cell intrinsic factors such as altered tumor suppressor responses and DNA damage response pathways with cell extrinsic factors exemplified by altered inflammatory and immune response pathways related to age‐associated tumor microenvironment changes. Other possible mechanistic factors not examined intensively in this study include age‐associated accumulation of somatic genetic and epigenetic alterations. Our demonstration that the putative tumor suppressor Cdh13 is hypermethylated and downregulated in the lung tumors of old mice suggest that cell intrinsic epigenetic modifications may influence cancer progression in older animals, consistent with epigenetic studies in human cancers (Feinberg, 2007). The role of age‐associated acquisition of cooperating somatic cancer driver mutations was not examined in our model. The less than twofold increase in genomic somatic mutations within normal mouse tissues between the ages of 4 and 20 months (Vijg et al., 2005) argues against a largely somatic mutation‐driven mechanism for the age‐dependent tumorigenesis differences described here. Thus, nonmutational cell intrinsic and extrinsic mechanisms may play a larger role in age‐dependent cancer initiation and progression. Nevertheless, further experiments on human cancer systems and animal cancer models will be necessary to resolve these issues.
For methods, refer to Methods S1 (Supporting information) section.
Author contributions
NP, RS, and LS performed the experiments. MG performed pathology and histopathology analyses. NP, LS, and LAD designed the experiments and analyzed the data. NP and LAD wrote the manuscript.
Funding
This work was supported by R21 grant AG035365 from the National Institute on Aging. L.A.D.—NIH R21 AG035365; L.A.D.—Ellison Medical Foundation; N.P.—Ellison Medical Foundation and American Federation for Aging Research.
Conflict of interest
None declared.
Supporting information
Acknowledgments
The authors thank David Corry and laboratory members for guidance with intranasal instillation, Susan V Tsang from Human Tissue Acquisition and Pathology Laboratory at Baylor College of Medicine for Ki67 staining quantitation, Comparative Pathology Laboratory at Baylor College of Medicine for tissue processing and sectioning, James Leroux at UT MD Anderson Cancer Center for lung section digital scans, Shixia Huang from Antibody‐Based Proteomics Core at Baylor College of Medicine for Luminex bead technology based cytokine analysis, the Integrated Microscopy Core supported with funding from the NIH (HD007495, DK56338, and CA125123), CPRIT (RP150578, RP120092), the Dan L. Duncan Cancer Center at Baylor College of Medicine and the John S. Dunn Gulf Coast Consortium for Chemical Genomics, Sushant M. Dutta for providing MATLAB‐based software to quantitate fluorescent intensity in immunostained cells, Neeti Agarwal and Elmoataz Abdel Fattah for feedback on the manuscript. Part of this work was conducted while NP was an Ellison Medical Foundation/AFAR Postdoctoral Fellow. Direct support of this work was provided to LAD by the National Institute on Aging (AG035365) and the Ellison Medical Foundation.
References
- Andreeva AV, Kutuzov MA (2010) Cadherin 13 in cancer. Genes Chromosom. Cancer 49, 775–790. [DOI] [PubMed] [Google Scholar]
- Armitage P, Doll R (1954) The age distribution of cancer and a multi‐stage theory of carcinogenesis. Br. J. Cancer 8, 1–12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Campisi J (2003) Cancer and ageing: rival demons?. Nat. Rev. Cancer 3, 339–349. [DOI] [PubMed] [Google Scholar]
- Coppe JP, Desprez PY, Krtolica A, Campisi J (2010) The senescence‐associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 5, 99–118. [DOI] [PMC free article] [PubMed] [Google Scholar]
- DePinho RA (2000) The age of cancer. Nature 408, 248–254. [DOI] [PubMed] [Google Scholar]
- DuPage M, Dooley AL, Jacks T (2009) Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat. Protoc. 4, 1064–1072. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Edwards MG, Anderson RM, Yuan M, Kendziorski CM, Weindruch R, Prolla TA (2007) Gene expression profiling of aging reveals activation of a p53‐mediated transcriptional program. BMC Genom. 8, 80. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Feinberg AP (2007) Phenotypic plasticity and the epigenetics of human disease. Nature 447, 433–440. [DOI] [PubMed] [Google Scholar]
- Feng Z, Hu W, Teresky AK, Hernando E, Cordon‐Cardo C, Levine AJ (2007) Declining p53 function in the aging process: a possible mechanism for the increased tumor incidence in older populations. Proc. Natl Acad. Sci. USA 104, 16633–16638. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Halazonetis TD, Gorgoulis VG, Bartek J (2008) An oncogene‐induced DNA damage model for cancer development. Science 319, 1352–1355. [DOI] [PubMed] [Google Scholar]
- Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, Jacks T, Tuveson DA (2001) Analysis of lung tumor initiation and progression using conditional expression of oncogenic K‐ras. Genes Dev. 15, 3243–3248. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jung M, Pfeifer GP (2015) Aging and DNA methylation. BMC Biol. 13, 7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kalluri R (2016) The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16, 582–598. [DOI] [PubMed] [Google Scholar]
- Kinner A, Wu W, Staudt C, Iliakis G (2008) Gamma‐H2AX in recognition and signaling of DNA double‐strand breaks in the context of chromatin. Nucleic Acids Res. 36, 5678–5694. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Krishnamurthy J, Torrice C, Ramsey MR, Kovalev GI, Al‐Regaiey K, Su L, Sharpless NE (2004) Ink4a/Arf expression is a biomarker of aging. J. Clin. Investig. 114, 1299–1307. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Krtolica A, Parrinello S, Lockett S, Desprez PY, Campisi J (2001) Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc. Natl Acad. Sci. USA 98, 12072–12077. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lasry A, Ben‐Neriah Y (2015) Senescence‐associated inflammatory responses: aging and cancer perspectives. Trends Immunol. 36, 217–228. [DOI] [PubMed] [Google Scholar]
- Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, Kiezun A, Hammerman PS, McKenna A, Drier Y, Zou L, Ramos AH, Pugh TJ, Stransky N, Helman E, Kim J, Sougnez C, Ambrogio L, Nickerson E, Shefler E, Cortes ML, Auclair D, Saksena G, Voet D, Noble M, DiCara D, Lin P, Lichtenstein L, Heiman DI, Fennell T, Imielinski M, Hernandez B, Hodis E, Baca S, Dulak AM, Lohr J, Landau DA, Wu CJ, Melendez‐Zajgla J, Hidalgo‐Miranda A, Koren A, McCarroll SA, Mora J, Lee RS, Crompton B, Onofrio R, Parkin M, Winckler W, Ardlie K, Gabriel SB, Roberts CW, Biegel JA, Stegmaier K, Bass AJ, Garraway LA, Meyerson M, Golub TR, Gordenin DA, Sunyaev S, Lander ES, Getz G (2013) Mutational heterogeneity in cancer and the search for new cancer‐associated genes. Nature 499, 214–218. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lopez‐Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G (2013) The hallmarks of aging. Cell 153, 1194–1217. [DOI] [PMC free article] [PubMed] [Google Scholar]
- de Magalhaes JP, Curado J, Church GM (2009) Meta‐analysis of age‐related gene expression profiles identifies common signatures of aging. Bioinformatics 25, 875–881. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Morrisette‐Thomas V, Cohen AA, Fulop T, Riesco E, Legault V, Li Q, Milot E, Dusseault‐Belanger F, Ferrucci L (2014) Inflamm‐aging does not simply reflect increases in pro‐inflammatory markers. Mech. Ageing Dev. 139, 49–57. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nordling CO (1953) A new theory on cancer‐inducing mechanism. Br. J. Cancer 7, 68–72. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pollard JW (2004) Tumour‐educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4, 71–78. [DOI] [PubMed] [Google Scholar]
- Rozhok AI, DeGregori J (2015) Toward an evolutionary model of cancer: considering the mechanisms that govern the fate of somatic mutations. Proc. Natl Acad. Sci. USA 112, 8914–8921. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sandoval J, Esteller M (2012) Cancer epigenomics: beyond genomics. Curr. Opin. Genet. Dev. 22, 50–55. [DOI] [PubMed] [Google Scholar]
- Schurman SH, Dunn CA, Greaves R, Yu B, Ferrucci L, Croteau DL, Seidman MM, Bohr VA (2012) Age‐related disease association of endogenous gamma‐H2AX foci in mononuclear cells derived from leukapheresis. PLoS One 7, e45728. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sedelnikova OA, Horikawa I, Zimonjic DB, Popescu NC, Bonner WM, Barrett JC (2004) Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double‐strand breaks. Nat. Cell Biol. 6, 168–170. [DOI] [PubMed] [Google Scholar]
- Sica A, Allavena P, Mantovani A (2008) Cancer related inflammation: the macrophage connection. Cancer Lett. 267, 204–215. [DOI] [PubMed] [Google Scholar]
- Sperka T, Wang J, Rudolph KL (2012) DNA damage checkpoints in stem cells, ageing and cancer. Nat. Rev. Mol. Cell Biol. 13, 579–590. [DOI] [PubMed] [Google Scholar]
- Tomasetti C, Vogelstein B (2015) Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 347, 78–81. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ugalde AP, Ramsay AJ, de la Rosa J, Varela I, Marino G, Cadinanos J, Lu J, Freije JM, Lopez‐Otin C (2011) Aging and chronic DNA damage response activate a regulatory pathway involving miR‐29 and p53. EMBO J. 30, 2219–2232. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vijg J, Busuttil RA, Bahar R, Dolle ME (2005) Aging and genome maintenance. Ann. N. Y. Acad. Sci. 1055, 35–47. [DOI] [PubMed] [Google Scholar]
- Wilson CY, Tolias P (2016) Recent advances in cancer drug discovery targeting RAS. Drug Discovery Today 21, 1915–1919. [DOI] [PubMed] [Google Scholar]
- Xue R, Yang C, Zhao F, Li D (2014) Prognostic significance of CDH13 hypermethylation and mRNA in NSCLC. Onco Targets Ther. 7, 1987–1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.